For the year ending 2025-12-31, NRXP made $1,225K in revenue. -$28,622K in net income. Net profit margin of -2336.49%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net patient service revenue | 1,225 | |||
| Cost of patient services | 505 | |||
| Research and development | 3,777 | |||
| Selling, general and administrative | 13,061 | |||
| Depreciation and amortization | 70 | |||
| Settlement expense (income) | 36 | |||
| Total operating expenses | 17,449 | |||
| Loss from operations | -16,224 | |||
| Interest income | 12 | |||
| Interest expense | 671 | |||
| Change in fair value of convertible notes payable | 3,939 | |||
| Change in fair value of warrant liabilities | 4,926 | |||
| Loss on issuance of registered direct offering | -730 | |||
| Loss on consideration shares and warrants | -1,277 | |||
| Convertible note default penalty | 0 | |||
| Loss on convertible note conversions | -6,201 | |||
| Loss from equity method investments | -35 | |||
| Gain on exercise of warrants | 5,369 | |||
| Total other expense, net | -12,398 | |||
| Net loss | -28,622 | |||
| Basic EPS | -1.34 | |||
| Basic Average Shares | 21,401,683 | |||
NRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. (NRXP)